VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

BSH 2018 | The evolution of MRD-guided therapy for leukemia

Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML). The evolution of MRD-guided therapies is timely, with MRD moving to being clinically relevant. Dr Dillion mentions multiple studies conclusively proving that MRD is one of the most, if not the most, relevant prognostic factor in AML. In the last few years, MRD measurement has been incorporated into treatment protocols, enabling physicians to choose the best treatment for each individual patient. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter